• A Corrigendum to this article was published on 14 February 2018

This article has been updated


Malaria is among the most serious infectious diseases affecting humans, accounting for approximately half a million deaths each year1. Plasmodium falciparum causes most life-threatening cases of malaria. Acquired immunity to malaria is inefficient, even after repeated exposure to P. falciparum2, but the immune regulatory mechanisms used by P. falciparum remain largely unknown. Here we show that P. falciparum uses immune inhibitory receptors to achieve immune evasion. RIFIN proteins are products of a polymorphic multigene family comprising approximately 150–200 genes per parasite genome3 that are expressed on the surface of infected erythrocytes. We found that a subset of RIFINs binds to either leucocyte immunoglobulin-like receptor B1 (LILRB1) or leucocyte-associated immunoglobulin-like receptor 1 (LAIR1). LILRB1-binding RIFINs inhibit activation of LILRB1-expressing B cells and natural killer (NK) cells. Furthermore, P. falciparum-infected erythrocytes isolated from patients with severe malaria were more likely to interact with LILRB1 than erythrocytes from patients with non-severe malaria, although an extended study with larger sample sizes is required to confirm this finding. Our results suggest that P. falciparum has acquired multiple RIFINs to evade the host immune system by targeting immune inhibitory receptors.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 14 February 2018

    Change history: Please see accompanying Corrigendum (http://doi.org/10.1038/nature25498). In Extended Data Fig. 1, the flow cytometry panel showing uninfected erythrocytes stained with LILRB5-Fc was inadvertently duplicated


  1. 1.

    World Health Organization. World Malaria Report 2016 (World Health Organization, 2016)

  2. 2.

    , , & Immunity to malaria: more questions than answers. Nat. Immunol. 9, 725–732 (2008)

  3. 3.

    , , & Sub-grouping and sub-functionalization of the RIFIN multi-copy protein family. BMC Genomics 9, 19 (2008)

  4. 4.

    , , , & Immune escape strategies of malaria parasites. Front. Microbiol. 7, 1617 (2016)

  5. 5.

    & Malaria parasites: the great escape. Front. Immunol. 7, 463 (2016)

  6. 6.

    , & Antigenic variation at the infected red cell surface in malaria. Annu. Rev. Microbiol. 55, 673–707 (2001)

  7. 7.

    , , & The pathogenic basis of malaria. Nature 415, 673–679 (2002)

  8. 8.

    et al. RIFINs are adhesins implicated in severe Plasmodium falciparum malaria. Nat. Med. 21, 314–317 (2015)

  9. 9.

    , , & Three is a crowd — new insights into rosetting in Plasmodium falciparum. Trends Parasitol. 33, 309–320 (2017)

  10. 10.

    & Specific recognition of virus-infected cells by paired NK receptors. Rev. Med. Virol. 14, 83–93 (2004)

  11. 11.

    & Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J. Hum. Genet. 60, 703–708 (2015)

  12. 12.

    et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186, 1809–1818 (1997)

  13. 13.

    et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7, 273–282 (1997)

  14. 14.

    et al. Microbially cleaved immunoglobulins are sensed by the innate immune receptor LILRA2. Nat. Microbiol. 1, 16054 (2016)

  15. 15.

    et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498–511 (2002)

  16. 16.

    et al. Structural conservation despite huge sequence diversity allows EPCR binding by the PfEMP1 family implicated in severe childhood malaria. Cell Host Microbe 17, 118–129 (2015)

  17. 17.

    et al. The structural basis for CD36 binding by the malaria parasite. Nat. Commun. 7, 12837 (2016)

  18. 18.

    , , & Surveillance of cell and tissue perturbation by receptors in the LRC. Immunol. Rev. 267, 117–136 (2015)

  19. 19.

    et al. A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. Nature 529, 105–109 (2016)

  20. 20.

    et al. Public antibodies to malaria antigens generated by two LAIR1 insertion modalities. Nature 548, 597–601 (2017)

  21. 21.

    et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J. Exp. Med. 203, 1419–1425 (2006)

  22. 22.

    et al. Variant proteins of the Plasmodium falciparum RIFIN family show distinct subcellular localization and developmental expression patterns. Mol. Biochem. Parasitol. 156, 51–61 (2007)

  23. 23.

    , , , & Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296, 1323–1326 (2002)

  24. 24.

    et al. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J. Biol. Chem. 281, 10439–10447 (2006)

  25. 25.

    et al. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J. Immunol. 192, 1536–1546 (2014)

  26. 26.

    et al. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect. Immun. 72, 5412–5418 (2004)

  27. 27.

    et al. Plasmodium falciparum var gene expression is modified by host immunity. Proc. Natl Acad. Sci. USA 106, 21801–21806 (2009)

  28. 28.

    et al. Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc. Natl Acad. Sci. USA 109, E1791–E1800 (2012)

  29. 29.

    et al. Expression of a type B RIFIN in Plasmodium falciparum merozoites and gametes. Malar. J. 11, 429 (2012)

  30. 30.

    , , & Plasmodium interspersed repeats: the major multigene superfamily of malaria parasites. Nucleic Acids Res. 32, 5712–5720 (2004)

  31. 31.

    et al. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24, 406–415 (1996)

  32. 32.

    et al. Plasmodium falciparum phospholipase C hydrolyzing sphingomyelin and lysocholinephospholipids is a possible target for malaria chemotherapy. J. Exp. Med. 195, 23–34 (2002)

  33. 33.

    , , , & Serum factors governing intraerythrocytic development and cell cycle progression of Plasmodium falciparum. Parasitol. Int. 49, 219–229 (2000)

  34. 34.

    et al. Allelic dimorphism-associated restriction of recombination in Plasmodium falciparum msp1. Gene 397, 153–160 (2007)

  35. 35.

    et al. PILRα is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 132, 935–944 (2008)

  36. 36.

    et al. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J. Immunol. 175, 4441–4449 (2005)

  37. 37.

    et al. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int. Immunol. 25, 235–246 (2013)

  38. 38.

    et al. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. Proc. Natl Acad. Sci. USA 111, 3787–3792 (2014)

  39. 39.

    , & Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063–1066 (2000)

  40. 40.

    , , & Centromere plasmid: a new genetic tool for the study of Plasmodium falciparum. PLoS One 7, e33326 (2012)

  41. 41.

    et al. Evidence for in vitro and in vivo expression of the conserved VAR3 (type 3) Plasmodium falciparum erythrocyte membrane protein 1. Malar. J. 11, 129 (2012)

  42. 42.

    et al. Structural analysis for glycolipid recognition by the C-type lectins Mincle and MCL. Proc. Natl Acad. Sci. USA 110, 17438–17443 (2013)

  43. 43.

    et al. Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery. Expert Rev. Vaccines 13, 75–85 (2014)

  44. 44.

    , , & Engineering large viral DNA genomes using the CRISPR–Cas9 system. Microbiol. Immunol. 58, 513–522 (2014)

  45. 45.

    et al. Cellulose filtration of blood from malaria patients for improving ex vivo growth of Plasmodium falciparum parasites. Malar. J. 16, 69 (2017)

  46. 46.

    et al. High efficacy of anti DBL4ε-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine 29, 437–443 (2011)

  47. 47.

    et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature 498, 502–505 (2013)

  48. 48.

    et al. IgG antibodies to endothelial protein C receptor-binding cysteine-rich interdomain region domains of Plasmodium falciparum erythrocyte membrane protein 1 are acquired early in life in individuals exposed to malaria. Infect. Immun. 83, 3096–3103 (2015)

Download references


We thank T. Mitamura for discussions, K. Saito for mass spectrometry analysis, M. Matsumoto and S. Matsuoka for technical assistance, the Thai and Tanzanian donors and the Japanese Red Cross Society for providing human erythrocytes and human plasma. This work was partly supported by the Japanese Initiative for Progress of Research on Infectious Disease for Global Epidemic from the Japan Agency for Medical Research and Development (AMED) (H.A.), the Platform Project for Supporting Drug Discovery and Life Science Research from AMED (J.T.), JSPS KAKENHI grant numbers JP16K08839 (K.H.), JP16H05195 (T.Su.), JP15K08531 (M.K.), MEXT KAKENHI grant numbers JP26117714 (H.A.), JP23117008 (T.T.), JP24115005 (H.A.), the Senri Life Science Foundation (K.H.), the Kato Memorial Bioscience Foundation (K.H.), the Danish Council for Independent Research grants 1333-00220 (C.W.W.) and 4004-00624B (T.L.), The Lundbeck Foundation (T.L.) and the United States National Institutes of Health (NIH R01HL130678, T.L.). F.S was supported by the Taniguchi Memorial Fellowship program.

Author information

Author notes

    • Takeshi Satoh

    Present address: Division of Systems Immunology, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.

    • Fumiji Saito
    •  & Kouyuki Hirayasu

    These authors contributed equally to this work.


  1. Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan

    • Fumiji Saito
    • , Takeshi Satoh
    • , Masako Kohyama
    • , Tadahiro Suenaga
    •  & Hisashi Arase
  2. Laboratory of Immunochemistry, WPI Immunology Frontier Research Centre, Osaka University, Suita, Osaka 565-0871, Japan

    • Kouyuki Hirayasu
    • , Kyoko Shida
    • , Masako Kohyama
    • , Tadahiro Suenaga
    •  & Hisashi Arase
  3. Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

    • Christian W. Wang
    •  & Thomas Lavstsen
  4. Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark

    • Christian W. Wang
    •  & Thomas Lavstsen
  5. National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania

    • John Lusingu
  6. Laboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan

    • Takao Arimori
    •  & Junichi Takagi
  7. Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan

    • Nirianne Marie Q. Palacpac
    • , Sawako Itagaki
    •  & Toshihiro Horii
  8. Department of Medical Zoology, School of Medicine, Mie University, Tsu, Mie 514-8507, Japan

    • Shiroh Iwanaga
  9. Department of Environmental Parasitology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan

    • Shiroh Iwanaga
  10. Division of Malaria Research, Proteo-Science Centre, Ehime University, Matsuyama, Ehime, 790-8577, Japan

    • Eizo Takashima
    •  & Takafumi Tsuboi
  11. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA

    • Marco Colonna


  1. Search for Fumiji Saito in:

  2. Search for Kouyuki Hirayasu in:

  3. Search for Takeshi Satoh in:

  4. Search for Christian W. Wang in:

  5. Search for John Lusingu in:

  6. Search for Takao Arimori in:

  7. Search for Kyoko Shida in:

  8. Search for Nirianne Marie Q. Palacpac in:

  9. Search for Sawako Itagaki in:

  10. Search for Shiroh Iwanaga in:

  11. Search for Eizo Takashima in:

  12. Search for Takafumi Tsuboi in:

  13. Search for Masako Kohyama in:

  14. Search for Tadahiro Suenaga in:

  15. Search for Marco Colonna in:

  16. Search for Junichi Takagi in:

  17. Search for Thomas Lavstsen in:

  18. Search for Toshihiro Horii in:

  19. Search for Hisashi Arase in:


F.S. and K.H. performed most of the binding and functional experiments, and analysed and discussed the data. T.Sa. performed limiting dilution experiments and assisted with ligand identification. C.W.W. performed binding and serological analyses in Tanzania. J.L. assisted with experiments in Tanzania. T.A. performed CD spectral analysis. K.S. prepared recombinant plasmids. N.M.Q.P. assisted with P. falciparum culture and cloning. S.It. assisted with P. falciparum culture. S.Iw. assisted with transgenic parasite experiments and provided Thai P. falciparum isolates. E.T. prepared wheat germ cell-free proteins. T.T. designed wheat germ cell-free protein expression system and discussed the data. M.K. assisted with functional experiments. T.Su. assisted with ligand identification. M.C. assisted with LILR analyses. J.T. assisted with protein experiments and discussed the data. T.L. assisted with experiments in Tanzania and discussed the data. T.H. assisted with P. falciparum experimental design and discussed the data. H.A. designed the study and analysed the data. All authors contributed to the writing of the manuscript.

Competing interests

Competing financial interests: Osaka university has filed a provisional patent application that covers the use of LILRB1-binding RIFINs as a possible target for malaria vaccine. F.S., K.H. and H.A. are listed as inventors.

Corresponding author

Correspondence to Hisashi Arase.

Reviewer Information Nature thanks P. Preiser and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Life Sciences Reporting Summary

  2. 2.

    Supplementary Information

    This file contains original gel images, gating strategy for flow cytometry analysis and sequence chromatogram of cloned rif genes.

Excel files

  1. 1.

    Supplementary Table 1

    This file contains information on peptides identified by mass spectrometry analyses.

  2. 2.

    Supplementary Table 2

    This file contains information on 33 different rif genes used for generating RIFIN-transgenic parasites.

  3. 3.

    Supplementary Table 3

    This file contains information on primers used to clone rif genes.

About this article

Publication history







By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.